Daraxonrasib Pancreatic Cancer Phase 3 Results
Decision brief
Answer first · skim in under a minute
Revolution Medicines has reported groundbreaking results for its pancreatic cancer drug, potentially transforming treatment protocols. This article explores the implications for the pharmaceutical industry.
Revolution Medicines’ pancreatic cancer drug daraxonrasib delivered practice-changing Phase 3 results at ASCO 2026: in previously treated metastatic disease, the oral RAS(ON) inhibitor roughly doubled median overall survival versus chemotherapy and cut death risk by 60%—a bar second-line PDAC rarely clears.
Contents10 sections
Key Takeaways
- RASolute 302 enrolled 500 previously treated metastatic PDAC patients comparing daraxonrasib 300 mg daily with investigator’s-choice chemo.
- RAS G12 median OS: 13.2 vs 6.6 months (HR 0.40); median PFS: 7.3 vs 3.5 months (HR 0.45); ORR: 33.2% vs 11.8%.
- Grade ≥3 TRAEs were lower on daraxonrasib (43.6%) than chemo (57.5%); TRAE discontinuation was 1.2% vs 11.2%.
- FDA Breakthrough Therapy and Orphan Drug designations were disclosed; the drug is not yet approved.
What did RASolute 302 show in pancreatic cancer?
According to the company’s May 31, 2026 GlobeNewswire ASCO plenary release, daraxonrasib met all primary and key secondary endpoints versus standard cytotoxic chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma.
Median follow-up was 8.5 months at the February 10, 2026 data cutoff. The design randomized patients to oral daraxonrasib or one of four investigator-choice chemo regimens used globally in this setting.
How meaningful were the survival and response deltas?
In the RAS G12 population (daraxonrasib n=228; chemo n=231), median OS was 13.2 months versus 6.6 months. The hazard ratio for death was 0.40 (95% CI 0.30–0.54; p<0.0001). PFS by blinded independent review showed median 7.3 versus 3.5 months (HR 0.45).
ITT analyses—including patients without identified tumor RAS mutations—showed median OS 13.2 versus 6.7 months (HR 0.40) and ORR 31.6% versus 11.2%. Those absolute gains explain why clinicians called the readout practice-changing for second-line metastatic PDAC.
What is the regulatory and access path?
The trial is registered as NCT06625320 on ClinicalTrials.gov. Revolution Medicines said it intends to file with global regulators, including an FDA New Drug Application under a Commissioner’s National Priority Voucher, and that FDA authorized an expanded access protocol.
The company also disclosed Breakthrough Therapy Designation and Orphan Drug Designation for previously treated metastatic PDAC harboring G12 mutations. Designations accelerate dialogue; they are not approvals.
Why does this matter for pancreatic cancer strategy?
Metastatic PDAC remains among the deadliest solid tumors. Per the company’s release citing U.S. epidemiology references, roughly 60,000 people are diagnosed and about 50,000 die annually in the United States, with about 80% presenting at advanced or metastatic stages and five-year metastatic survival near 3%.
More than 90% of PDAC tumors harbor RAS mutations, which is why a multi-selective RAS(ON) inhibitor that works across G12D, G12V, G12R and related genotypes is strategically different from narrow allele-specific approaches. A randomized oral agent that doubles median OS versus chemo resets competitive expectations for the entire RAS-pathway class.
Business development teams should model second-line share capture against chemo backbones, watch combination strategies in earlier lines, and avoid assuming allele-specific KRAS inhibitors automatically match multi-selective RAS(ON) outcomes without head-to-head data. Licensing screens should also reprice second-line PDAC assets that cannot clear a 13-month median OS bar in similar populations.
For EU and U.S. commercial leads, the next operating question is sequencing: whether daraxonrasib becomes the default post-gemcitabine or post-FOLFIRINOX option, and how quickly centers can operationalize oral RAS(ON) monitoring for rash, stomatitis, and rare pneumonitis while chemotherapy infusion capacity is freed.
What safety signals should medical affairs track?
- Grade ≥3 TRAE rate: 43.6% daraxonrasib vs 57.5% chemo.
- Daraxonrasib Grade ≥3 rash 14% and stomatitis 12%.
- Treatment-related serious adverse events: 10.8% vs 18.7%.
- One Grade 5 pneumonitis TRAE (0.4%) on daraxonrasib.
What remains unproven?
RASolute 302 does not establish first-line standard-of-care status, OS benefit in every molecular subset beyond disclosed analyses, or superiority versus every emerging RAS inhibitor. Pricing, companion diagnostic needs, and guideline adoption remain open. “Practice-changing” here refers to the magnitude of randomized OS benefit versus chemo, not an already rewritten NCCN/ESMO algorithm.
Cross-trial comparisons with historical second-line chemo series are also insufficient for causal claims; only the randomized control within RASolute 302 supports the hazard ratios cited above. Combination regimens, adjuvant settings, and RAS-wild-type biology need dedicated studies before broader slogans about curing pancreatic cancer are warranted.
Related NovaPharma coverage
- Revolution Medicines' RAS Leadership at ASCO
- Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
- BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
Frequently Asked Questions
What practice-changing pancreatic cancer results did Revolution Medicines report?
In Phase 3 RASolute 302, oral daraxonrasib improved median overall survival to 13.2 months versus 6.6 months with chemotherapy in RAS G12 mutant previously treated metastatic PDAC (HR 0.40), with similar ITT results.
How many patients were enrolled in RASolute 302?
The global randomized Phase 3 trial enrolled 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma, randomized to daraxonrasib 300 mg once daily or investigator’s-choice chemotherapy (NCT06625320).
Has FDA approved daraxonrasib for pancreatic cancer?
No. Daraxonrasib is investigational. Revolution Medicines plans regulatory submissions including an FDA NDA under a Commissioner’s National Priority Voucher; Breakthrough Therapy and Orphan Drug designations were disclosed for previously treated metastatic PDAC with G12 mutations.
Primary Sources
Revolution Medicines pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
